cis-2,4,6-Trimethylmorpholin | 38574-43-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: cis-2,4,6-Trimethylmorpholin
• 英文别名: N-Methyl-trans-2,6-dimethylmorpholin；2,4,6-trimethyl-morpholine；(2R,6S)-2,4,6-trimethylmorpholine；(2S,6R)-2,4,6-trimethylmorpholine
• CAS: 38574-43-5
• 化学式: C₇H₁₅NO
• 分子量: 129.202
• InChiKey: APOJIILNJVLCQE-KNVOCYPGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12.5
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• [EN] SOMATOSTATIN MODULATORS AND USES THEREOF<br/>[FR] MODULATEURS DE LA SOMATOSTATINE ET UTILISATIONS DE CES DERNIERS
  申请人：CRINETICS PHARMACEUTICALS INC

  公开号：WO2019023278A1

  公开（公告）日：2019-01-31

  Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.

  本文描述了一些肽类调节剂化合物，制备这类化合物的方法，包含这类化合物的药物组合物和药物，以及利用这类化合物治疗需要调节生长抑素活性的疾病、症状或疾病的方法。
• [EN] PYRIMIDINE, PYRIDINE AND TRIAZINE DERIVATIVES AS MAXI-K CHANNEL OPENERS.<br/>[FR] DÉRIVÉS DE PYRIMIDINE, PYRIDINE ET TRIAZINE EN TANT QU'OUVREURS DE CANAUX MAXI-K
  申请人：MITSUBISHI TANABE PHARMA CORP

  公开号：WO2009125870A1

  公开（公告）日：2009-10-15

  A compound of formula (A); wherein ring A is an aromatic ring or a heteroaromatic ring; R1 is independently halogen, cyano, etc., each of X1, X2 and X3 is CR2 or nitrogen, R2 is independently hydrogen, etc., n is 0, 1, 2, 3 or 4; -D-Y is -O-CH2COOH, etc, and G is a substituted amino, a substituted heterocyclic group, etc, or a pharmaceutical acceptable salt thereof, has activities of opening BK channels.

  化合物的结构式（A）；其中环A是芳香环或杂芳环；R1独立地是卤素、氰基等；X1、X2和X3中的每一个是CR2或氮，R2独立地是氢等；n为0、1、2、3或4；-D-Y是-O-CH2COOH等；G是取代氨基、取代杂环基等，或其药用可接受盐，具有开放BK通道的活性。
• NOVEL SUBSTITUTED TRIAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS
  申请人：Van Brandt Sven Franciscus Anna

  公开号：US20120295891A1

  公开（公告）日：2012-11-22

  The present invention is concerned with novel substituted triazole derivatives of Formula (I) wherein Het 1 , R 1 , R 2 , A 1 , A 2 , A 3 , A 4 , L 1 , and L 2 have the meaning defined in the claims. The compounds according to the present invention are useful as gamma secretase modulators. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.

  本发明涉及具有以下式（I）的新型取代三唑衍生物，其中Het1，R1，R2，A1，A2，A3，A4，L1和L2的含义如权利要求中所定义。根据本发明的化合物可用作γ-分泌酶调节剂。本发明还涉及制备这种新型化合物的方法，包括将所述化合物作为活性成分的药物组合物以及将所述化合物用作药物的用途。
• Hepatitis C Virus Inhibitors
  申请人：Bristol-Myers Squibb Company

  公开号：US20130183269A1

  公开（公告）日：2013-07-18

  The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.

  本公开涉及抗病毒化合物，更具体地涉及能够抑制丙型肝炎病毒（HCV）编码的NS5A蛋白功能的化合物组合，包括这种组合的组成物，以及抑制NS5A蛋白功能的方法。
• LIPIDS, LIPID COMPOSITIONS, AND METHODS OF USING THEM
  申请人：BARYZA Jeremy

  公开号：US20110200582A1

  公开（公告）日：2011-08-18

  Disclosed are formulation and optimization protocols for delivery of therapeutically effective amounts of biologically active agents to liver, tumors, and/or other cells or tissues. Also provided are compositions and uses for cationic lipid compounds of formula (I). The invention also relates to compositions and uses for stealth lipids of formula (XI). Also provided are processes for making such compounds, compositions, and formulations, plus methods and uses of such compounds, compositions, and formulations to deliver biologically active agents to cells and/or tissues.

  本文披露了用于将生物活性剂量有效传递至肝脏、肿瘤和/或其他细胞或组织的配方和优化方案。还提供了具有化学式（I）的阳离子脂质化合物的组成和用途。该发明还涉及具有化学式（XI）的隐身脂质的组成和用途。还提供了制备这种化合物、组成物和配方的方法，以及利用这些化合物、组成物和配方将生物活性剂传递至细胞和/或组织的方法和用途。